Appetite suppression typically becomes more noticeable as your dosage increases over time and your system adapts
Bugianesi, E., Moscatiello, S., Ciaravella, M
Retrieved February 17, 2023, from Centers for Disease Control and Prevention
Choose Semaglutide If You have established cardiovascular disease (prior heart attack, stroke, stent, peripheral artery disease) You're over 50 with multiple cardiovascular risk factors (hypertension, high LDL, smoking history, family history) You've already lost most of the weight you want to lose and you're switching from short-term weight loss to long-term metabolic protection You want the longest-running real-world safety data on a GLP-1 Choose Tirzepatide If Your primary goal is maximum weight loss in the shortest timeframe You don't have established cardiovascular disease You've plateaued on semaglutide and need stronger appetite suppression You tolerate tirzepatide better (some people get less GI upset on dual agonism) What's Still Available After the FDA Crackdown 503A compounding pharmacies continue to prepare both peptides for documented medical need
If these trials prove successful, analysts expect regulatory submission around 2026, with potential market availability in late 2026 or 2027
Lets talk money, because thats ultimately what determines whether this is worth your time
